"The Histolix technology heralds a radically new approach to the preparation of the images required by pathologists to interpret biopsy specimens. Since its origins in the 19th century, pathology has been constrained by a laborious and time consuming process of fixation, dehydration, paraffinization, rehydration and staining requiring skilled technologists and expensive equipment. Histolix technology promises to dramatically reduce the time required to prepare these images, and simultaneously permit a direct-to-digital pathologic evaluation framework, enabling pathology to emulate radiology in rapid evaluation and dissemination of biopsy findings. Histolix makes preparation of digital images suitable for pathologic evaluation accessible to a wide range of users, including satellite lab facilities, veterinary laboratories, and resource constrained laboratories all over the world."
Doctor Allen Gown
Allen Gown, MD
Founder, PhenoPath Laboratories, Seattle, WA
Clinical Professor of Pathology, University of British Columbia, Vancouver BC

Histolix has closed its initial SAFE note, the funds of which will be utilized to conduct an equivalency validation over multiple tissue types with expert third party read. The study is expected to be completed by the fourth quarter 2021 at which time we will set the valuation of our upcoming A round. A secondary bridge of approximately $500K will be sourced coming into the A round.

2017

Histolix Founders Receives $1.9 million in grants to initiate Histolix technology

2018

First Histolix prototype completed at UC Davis

2019

UC Davis Patents Filed and Histolix Incorporated

2021

Histolix Board and Executive Team Expansion (Q1)

Rob Royea appointed as CEO (Q1)

Oran Muduroglu appointed as Chairman of the Board (Q1)

First Histolix Funds raised (Q2)

Ben Weiss, Lead Investor joins Board (Q2)

Equivalency Validation Trail (EVT) Initiates (Q2)

First Histolix office opens in Sacramento, CA (Q2)

Fourth generation Histolix prototype completed (Q3)

Dr. Allen Gown, internationally recognized pathologist joins as advisor (Q3)

3rd Party Expert Evaluation of EVT concludes (Q4)

Series A Round Opens (Q4)

FDA Lumpectomy Trial Initiates at UC Davis (Q4)

2022

Commercial Product Development Begins (Q1)

FDA Lumpectomy Trial Concludes (Q3)

2023

FDA Clearance (Q1)

Commercial Launch (Q2)